Technology

The Rumi Platform: Standardized Human Neural Organoids

Rumi Scientific has developed a transformative, proven process for screening and testing genetic diseases – faster and more effectively than ever before.

Rumi’s technology is a powerful high-throughput organoid-like platform which mimics the development of the human brain, at high-speed. We have unprecedented ability to identify and quantify differences between diseased and healthy cells; and with our machine-learning algorithms, we are able to see which compounds have reversed diseased cells back to health, thus predicting the therapeutic effect a drug could have on a human’s diseased brain tissues. Our platform does not require a priori hypotheses of disease pathways, instead utilizing phenotypes.

Breakthrough 1

The Human Model

We can mimic the development of the human nervous system and the complex biology behind this process.

By combining the work of Dr. Ali Brivanlou and Dr. Eric Siggia, Rumi Scientific has fused stem cell biology and physics to create a transformative method of human embryonic stem cells which self-organize to generate a signature defined by geometry and size. Using cell lines with disease-causing mutations, Rumi can test compounds directly on disease models.

Breakthrough 2

The Disease Model

We can mimic the development of the nervous system of a person that has a disease-causing mutation.

Rumi has utilized isogenic cell lines with the Huntington’s Disease mutation and identified a signature on Rumi’s neuroloids. We have also identified compounds capable of reversing the Huntington’s signature back to normal.

Breakthrough 3

A High-throughput Platform

We can apply Breakthrough 1 and 2 in thousands of identical replicates.

Rumi Scientific’s proprietary technology has created a unique and transformative screening platform for genetic diseases to identify potential treatments. No other existing platform can achieve the qualitative and quantitative level of resolution obtained with our technology.

Breakthrough 4

Phenotypic Analysis using Artificial Intelligence

We can achieve unbiased analysis using deep neural networks to extract toxicity and efficacy.

The Rumi technology is the result of cooperation by the heads of the Physics and Stem Cell Biology Laboratories at Rockefeller University, who have worked together for over a decade, combining inputs from the disciplines of biology and physics. The result is a revolution in the landscape of drug discovery using a micropattern technology as a new path to grow human embryonic stem cells. In the Rumi technology, human embryonic stem cells (hESCs) self-organize, replicating the processes which occur in vivo during a cell’s early embryonic development. By recapitulating the ongoing cell-to-cell signaling and studying the relationship between cells as they differentiate to give rise to different human cell types, our Rumi technology can be applied to solve myriad problems in the drug discovery process.

Numerous Advantages over Existing Processes

Rumi Scientific’s platform outperforms existing drug discovery technologies. What we start with can become anything.

Human Models + Isogenic Lines

Under 14% of drug development programs make it to Phase I. One reason for this low success rate is the lack of accurate and representative human models. Rumi's platform uses human embryonic stem cell lines that are genetically identical except for the gene causing the disease. As a result, our technology creates a better physiological disease model: Human isogenic lines allow us to accurately associate a phenotype with the gene edited, as all other genes remain the same.

Phenotypic Mining & Discovery

Rumi's platform reveals phenotypes which could not previously be found.<br /> High-throughput screening against these phenotypes identifies hits to jumpstart the discovery process, unbiased with regard to pathway or target.

Unbiased AI-driven Analysis

Using proprietary AI-driven methodology, we are able to analyze our phenotypic data output without bias, and without relying on pre-determined phenotypes, thus better measuring the biological complexity of human tissues, and resulting in previously unseen Z' scores.

Universally Applicable

Rumi Scientific’s platform is disease-agnostic. The phenotypic characteristics are determined without bias by our machine learning algorithms, thus allowing the platform to extend to other diseases.

Specificity/Toxicity

Our unique quantification methods can additionally categorize compounds with respect to their toxicity/off-target effects and their therapeutic effect. This creates an information-rich pipeline that is necessary for the success of drug development.

Clinical Targets

The use of Rumi's platform for drug discovery is not only enables a more efficient discovery process of drug candidates, but also assists in the development of more efficient clinical strategies. As Rumi's models focus on drug effects for patients with a specific genetic fingerprint, future clinical trials could be designed to target patients with those genetic markers, which would allow for smaller, more targeted clinical trials and a faster development process.

Comparative Analysis: Pre-clinical Platforms

Rumi Scientific’s platform outperforms existing drug discovery technologies

	Rumi	2D Cell Models	3D Organoids	In Silico
Throughput
In Vivo Relevance				?
Analytical Tools
Standardization				n.a.
Broad Applicability

I would like to learn about Rumi Scientific’s novel discoveries to treat genetic diseases.

YES, TELL ME MORE